Ricevi le ultime notizie sulle azioni Sonoma Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SNOA

Ultime notizie per

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals Inc

Earnings

Press Releases

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Events

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Legal

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

News

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced

Penny Stocks

Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

SNOA

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Akanda

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Warrant

Aspire Biopharma Hldgs

Clearmind Medicine

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Impact BioMedical

IM Cannabis

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

Q/C Technologies

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

Comments

Sonoma Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO